Changes in forced vital capacity over time in systemic sclerosis: Application of group-based trajectory modelling

Rheumatology (United Kingdom)

Volumn 54, Issue 8, 2015, Pages 1464-1471

  Man, Ada ^a   Davidyock, Todd ^a   Ferguson, Laura T ^a   Ieong, Michael ^a   Zhang, Yuqing ^a   Simms, Robert W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Forced vital capacity; Group based modelling; Interstitial lung disease; Outcomes; Patient stratification; Pulmonary function; Scleroderma; Systemic sclerosis; Trajectories

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLUSTER ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; COVARIANCE; DIAGNOSTIC TEST ACCURACY STUDY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; STATISTICAL MODEL; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY;

EID: 84939474861     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev016     Document Type: Article

References (34)

1. Walker UA, Tyndall A, Czirják L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66: 754-63.
2. Steele R, Hudson M, Lo E, Baron M. Canadian Scleroderma Research Group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012;64:519-24.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66: 940-4.
4. Greenwald GI, Tashkin DP, Gong H et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med 1987;83:83-92.
5. Peters-Golden M, Wise RA, Schneider P. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine 1984;63:221-31.
6. Schneider PD, Wise RA, Hochberg MC, Wigley FM. Serial pulmonary function in systemic sclerosis. Am J Med 1982; 73:385-94.
7. Khanna D, Tseng C-H, Farmani N et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011;63:3078-85.
8. Merkel PA, Silliman NP, Clements PJ et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2012;64:3420-9.
9. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 2010;6:109-38.
10. Nagin D. Group-based modeling of development. Cambridge, MA, USA: Harvard University Press, 2005.
11. Shand L, Lunt M, Nihtyanova S et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007;56: 2422-31.
12. Furst D, Khanna D, Matucci-Cerinic M et al. Systemic sclerosis-continuing progress in developing clinical measures of response. J Rheumatol 2007;34:1194-200.
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
14. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-64.
15. Sterk PJ, Fabbri LM, Quanjer PH et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:53-83.
16. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Method Res 2001;29:374-93.
17. Allen NB, Siddique J, Wilkins JT et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA 2014;311: 490-7.
18. Gill TM, Gahbauer EA, Han L, Allore HG. Trajectories of disability in the last year of life. N Engl J Med 2010;362: 1173-80.
19. Jones BL, Nagin DS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Sociol Method Res 2007;35:542-71.
20. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM. When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol 2005;162:267-78.
21. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
22. Assassi S, Sharif R, Lasky RE et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
23. Colp CR, Riker J, Williams MH Jr. Serial changes in scleroderma and idiopathic interstitial lung disease. Arch Intern Med 1973;132:506-15.
24. Plastiras SC, Karadimitrakis SP, Ziakas PD et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55: 598-602.
25. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62: 146-50.
26. Tashkin DP, ElashoffD, Roth MD et al. Predictors of change in % predicted FVC over time in scleroderma (SSc) interstitial lung disease (ILD): findings from the scleroderma lung study (SLS). In: C15. ILD and Connective Tissue Disorders I. American Thoracic Society International Conference Abstracts. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts. A3940 (18 February 2015, date last accessed).
27. Hasegawa M, Asano Y, Endo H et al. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study. Rheumatology 2012;51:129-33.
28. Peto R. The horse-racing effect. Lancet 1981;2:467-8.
29. Trad S, Amoura Z, Beigelman C et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006;54:184-91.
30. Tzouvelekis A, Harokopos V, Paparountas T et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med 2007; 176:1108-19.
31. Beyer C, Schett G, Gay S, Distler O, Distler JHW. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther 2009;11:220.
32. Mittoo S, Robinson D, Hudson M, Baron M. Predicting lung function decline in systemic sclerosis (SSc). Ann Rheum Dis 2010;69(Suppl 2):A27.
33. Greidinger EL, Flaherty KT, White B et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998;114:801-7.
34. Jacobsen S, Halberg P, Ullman S et al. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol 1997;16: 384-90.